Tonix Pharmaceuticals stock halted ahead of FDA approval news
BRISBANE, Calif. - CareDx, Inc. (NASDAQ:CDNA), a precision medicine company specializing in transplant patient care, has announced the publication of a study in Transplant International showing that its AlloSeq cfDNA test reliably detects kidney allograft rejection. This finding aligns with the performance of its established AlloSure Kidney test. According to InvestingPro data, CareDx maintains a strong financial position with a market capitalization of $1.31 billion and an impressive current ratio of 4.1, indicating robust operational liquidity. Analysis from InvestingPro suggests the stock is currently undervalued based on their proprietary Fair Value calculations.
The study, a large-scale multicenter effort, included 580 kidney transplant patients from three European transplant centers. It demonstrated that AlloSeq cfDNA could accurately identify instances of allograft rejection, with significant differences observed between rejection and non-rejection cases (p
According to Dr. Alexandre Loupy, a leading nephrologist and epidemiologist involved in the study, these results support the potential for wider adoption of cell-free DNA testing in monitoring transplant patients for early signs of rejection. The company’s strong financial health score of "GOOD" from InvestingPro suggests it has the resources to support this expansion.
John W. Hanna, CareDx’s President and CEO, expressed optimism that the data will encourage the use of AlloSeq cfDNA for monitoring kidney transplants internationally. With around 18,000 kidney transplants occurring annually in the European Union, early detection of rejection using AlloSeq cfDNA could enable earlier intervention, potentially preventing irreversible organ damage and improving patient outcomes.
AlloSeq cfDNA is currently available in the European Union and the United Kingdom (TADAWUL:4280) with CE-IVD marking, but it is not yet available in the United States.
CareDx emphasizes that the published findings could enhance the care of transplant patients, although the company cautions that forward-looking statements are subject to risks and uncertainties. This includes the possibility that the benefits of AlloSeq cfDNA and AlloSure may not be realized as expected.
The information in this article is based on a press release statement from CareDx, Inc. Investors should note that the company’s next earnings report is scheduled for February 26, 2025. For comprehensive analysis and detailed insights, access the full CareDx Pro Research Report, available exclusively on InvestingPro.
In other recent news, CareDx has reported preliminary financial results for the fourth quarter and the full year ending December 31, 2024. The company anticipates a significant revenue increase, with fourth-quarter earnings expected to be between $85 million and $86 million, reflecting approximately 30% year-over-year growth. Despite this, CareDx expects a GAAP loss of about $32 million to $34 million for the fourth quarter, although adjusted EBITDA is projected to show a gain between $8 million and $9 million. For the full year 2024, revenue is forecasted to be in the range of $332 million to $333 million, with a GAAP loss anticipated between $58 million and $60 million. In other developments, CareDx has revised its compensation policy for non-employee directors, eliminating extra quarterly retainers and adjusting stock award vesting schedules. Additionally, CareDx has expanded into hematology oncology through a partnership with TC BioPharm to use its AlloCell solution in the ACHIEVE clinical trial. This trial aims to assess the efficacy of a gamma-delta T-cell therapy for patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome. These recent developments reflect CareDx’s strategic moves in financial management and clinical expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.